Pharma

Scripting independent India’s pharma industry journey from non-existent to a world leader

Going forward, emphasis should be on creating industry-academia linkage to promote R&D activities and effort should be made to upgrade pharmacy courses and skilling of new talent.

DCGI shares draft guidelines for pharma giants manufacturing, distributing COVID-19 vaccines

Dr Balram Bhargava, Director-General of ICMR said, "There are three things for a vaccine--(i) the safety, (ii) immunogenicity, and (iii) the efficacy."

Lupin Q4 results: Consolidated net profit rises 35% to Rs 390 cr; income from operations marginally down

Drug firm Lupin has reported a 34.55 percent rise in its consolidated net profit to Rs 389.63 crore for the quarter ended March 2020 mainly on account of robust sales in the domestic market and lower tax expenses

Earnings of Sensex companies to decline up to 8% this year on economic concerns; fiscal stimulus may help recovery: Analyst

At present, Indian indices are under-performing as compared to others and a package from the government can help cover the ground, he said.

Glenmark to study potential COVID-19 drug combination; to look to enroll 158 hospitalised patients

On 1 May, Glenmark Pharmaceuticals said it has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients.

Sensex drops 260 points, Nifty settles below 9,050-mark at close of trading session; banking, financial stocks drag

Sensex tumbled 260 points on Friday, dragged by losses in banking and financial stocks as RBI's rate cut and other measures to prop up the economy failed to meet market expectations.

Markets close day's session on buoyant note: Sensex up 622 points, Nifty above 9,050-mark; HDFC top gainer, surges over 5%

The Sensex settled 622.44 points or 2.06 percent higher at 30,818.61, while the NSE Nifty rose 187.45 points, or 2.11 percent, to end at 9,066.55

Market ends on positive note; Sensex jumps 637 points, Nifty above 9,350; Re settles higher at Rs 75.46 against dollar

The Nifty bank index was up by 4 percent. Besides, sharp buying was also witnessed in the auto and metal stocks.

Cipla inks licensing pact with Gilead Sciences for potential COVID-19 treatment drug remdesivir

Homegrown pharma major Cipla Ltd on Wednesday said it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of investigational drug remdesivir, a potential therapy for COVID-19

Hetero inks licensing agreement with Gilead for manufacturing, distribution of remdesivir

Domestic pharma major Hetero on Wednesday said it has entered into a licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19